Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction?

ISRCTN ISRCTN88675588
DOI https://doi.org/10.1186/ISRCTN88675588
Secondary identifying numbers N/A
Submission date
20/03/2007
Registration date
02/05/2007
Last edited
28/09/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof John Kingdom
Scientific

Department of Obstetrics & Gynecology
700 University Ave, 3rd Floor
Toronto
M5G 1Z4
Canada

Email jkingdom@mtsinai.on.ca

Study information

Study designRandomised controlled open label trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleDoes heparin improve pregnancy outcomes for women with evidence of placental dysfunction? A randomised controlled trial
Study acronymHEPRIN: HEparin for the PRevention of complications related to placental INsufficiency
Study objectivesThe administration of heparin to women with identified placental dysfunction will:
1. Reduce the risk of intra-uterine foetal death
2. Reduce the risk of other adverse pregnancy outcomes
Ethics approval(s)Approval received from the Mount Sinai Hospital (Canada) on the 6th March 2007.
Health condition(s) or problem(s) studiedPregnancy; placental dysfunction
InterventionDaily subcutaneous heparin (7500 units twice daily from randomisation [18 to 24 weeks gestation] until birth) versus standard care (no medication administered).

Follow up was performed on women and their infants up to four months of age; longer term follow up may be possible subject to further successful funding.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Heparin
Primary outcome measure1. Intrauterine foetal death
2. Adverse pregnancy complications (including pre-eclampsia, preterm birth, infant small for gestational age, neonatal death)

These will be assessed during the antenatal period (in relation to side effects of medication) and after the time of birth for birth and postpartum outcomes.
Secondary outcome measures1. Adverse neonatal outcomes
2. Adverse maternal outcomes
3. Maternal quality of life and emotional wellbeing: this will be assessed at four months postpartum using standard questionnaires (the Edinburgh depression scale; the 36-item Short Form health survey [SF-36] and the Speilberger anxiety trait questionnaires)
4. Placental pathology

These will be assessed during the antenatal period (in relation to side effects of medication) and after the time of birth for birth and postpartum outcomes.
Overall study start date21/03/2007
Completion date28/02/2010

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target number of participants102 women
Key inclusion criteria1. Women with a singleton pregnancy at 18 to 22 weeks gestation
2. Evidence of placental dysfunction in their current pregnancy as determined by two or more of the following:
a. abnormal ultrasonographic placental morphology
b. abnormal uterine artery Doppler waveforms
c. one or more abnormal biochemical markers on first or second trimester maternal serum screening
Key exclusion criteria1. Women with known positive thrombophilic screening
2. Known lethal foetal anomaly
3. Any contraindication to heparin therapy or continuation of the pregnancy (e.g., chorioamnionitis requiring delivery)
4. Clinical need for heparin therapy during pregnancy (e.g., previous venous thrombo-embolic episode)
5. Multiple pregnancy
6. Hypertension
7. Language barrier requiring official translator
Date of first enrolment21/03/2007
Date of final enrolment28/02/2010

Locations

Countries of recruitment

  • Canada

Study participating centre

Department of Obstetrics & Gynecology
Toronto
M5G 1Z4
Canada

Sponsor information

University of Toronto (Canada)
University/education

Mt Sinai Hospital
600 University Avenue
Toronto
M5G 1Z4
Canada

Website http://www.utoronto.ca/
ROR logo "ROR" https://ror.org/03dbr7087

Funders

Funder type

Research organisation

The Physicians Services Incorporated Foundation (Canada)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan